A monocentric analysis of the long-term safety and efficacy of crizotinib in relapsed/refractory ALK+ lymphomas

Blood Adv. 2023 Feb 14;7(3):314-316. doi: 10.1182/bloodadvances.2022007538.

Authors

Giovanni Rindone^{1

2}, Andrea Aroldi^{1

2}, Elisa Bossi^{1

2}, Luisa Verga¹, Giovanni Zambrotta^{1

2}, Sara Tarantino^{1

2}, Rocco Piazza^{1

2}, Lara Mussolin³, Roberto Chiarle^{4

5}, Carlo Gambacorti-Passerini^{1

2}

Affiliations

¹ Hematology Division, San Gerardo Hospital, Monza, Italy.
² Department of Medicine and Surgery, University of Milano-Bicocca, Milan, Italy.
³ Department of Woman's and Child's Health, University of Padova, Padova, Italy.
⁴ Department of Molecular Biotechnology and Health Sciences, University of Turin, Turin, Italy.
⁵ Department of Pathology, Boston Children's Hospital and Harvard Medical School, Boston, MA.

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Anaplastic Lymphoma Kinase
Crizotinib / adverse effects
Humans
Lymphoma*
Receptor Protein-Tyrosine Kinases*

Substances

Crizotinib
Receptor Protein-Tyrosine Kinases
Anaplastic Lymphoma Kinase

Grants and funding

R01 CA196703/CA/NCI NIH HHS/United States